🟠 Moderate Evidence
Mitochondria function as metabolic control centres that regulate far more than cellular energy production, according to emerging research published in Signal Transduction and Targeted Therapy. Rather than acting as passive “power plants,” these organelles actively direct inflammation, aging pathways, and disease progression through energy signalling mechanisms that orchestrate cellular behaviour across multiple organ systems.
Key takeaways
- Mitochondria function as regulatory hubs controlling inflammation, ageing, and disease progression rather than solely producing energy
- Damaged mitochondria release internal components triggering immune-mediated inflammation independently of infection
- Accumulation of dysfunctional mitochondria with age drives oxidative damage and low-grade systemic inflammation
- Neurodegenerative disease, diabetes, heart disease, and cancer share a common mitochondrial dysfunction pathway despite affecting different tissues
- Mitochondrial health interventions may simultaneously improve multiple seemingly unrelated disease outcomes
Mitochondrial dysfunction as a shared pathological pathway across disease categories
Seven major disease groups with distinct clinical presentations but common mitochondrial failure mechanisms
Source: Signal Transduction and Targeted Therapy (2025) | Georgian Medical Journal News
Energy signalling: beyond ATP production
Mitochondria produce adenosine triphosphate (ATP), but their role extends far beyond energy generation. According to research synthesized in Signal Transduction and Targeted Therapy, mitochondria function as metabolic sensors that determine how energy is produced, where it is distributed, and when cells alter their functional behaviour. Energy itself operates as an intercellular signalling molecule that communicates metabolic status to the nucleus and influences gene expression.
This distinction matters clinically. Cells with impaired mitochondrial function may produce adequate ATP in isolation but fail to maintain proper energy signalling between organelles and the nucleus. This disconnect disrupts coordinated cellular responses even when total energy availability appears sufficient on biochemical assays.
Damaged mitochondria as drivers of sterile inflammation
When mitochondria sustain damage from oxidative stress, metabolic excess, or genetic defects, they release internal molecular components into the cytoplasm. The immune system recognizes these released factors—including mitochondrial DNA and reactive oxygen species—as danger-associated molecular patterns (DAMPs). According to research on mitochondrial dysfunction and innate immunity, this recognition triggers inflammatory cascades independently of pathogenic infection.
This mechanism explains why chronic inflammation persists in many age-related and metabolic diseases despite negative infection markers. The cellular immune response becomes chronically activated by endogenous mitochondrial damage rather than external pathogens. Over time, this low-grade sterile inflammation contributes to tissue remodelling, fibrosis, and organ dysfunction.
Mitochondrial damage initiates immune-mediated inflammation without infection, creating a self-perpetuating cycle where cellular energy failure drives systemic inflammation that further compromises mitochondrial function in neighbouring cells.
— Signal Transduction and Targeted Therapy (2025)
Mitochondrial ageing and the accumulation hypothesis
Human ageing involves progressive decline in the cell’s ability to recognize, segregate, and eliminate damaged mitochondria—a process termed mitophagy. As organisms age, dysfunctional mitochondria accumulate within cells rather than being cleared. These defective organelles consume cellular resources while producing excess reactive oxygen species and contributing to oxidative damage.
The accumulation of damaged mitochondria creates a vicious cycle: oxidative damage impairs mitophagy further, reducing the cell’s capacity to maintain mitochondrial quality control. This deterioration drives the low-grade systemic inflammation associated with ageing, a state sometimes termed “inflammageing.” Multiple tissues become progressively compromised simultaneously, explaining why ageing affects virtually every organ system rather than causing isolated organ failure.
Evidence published in cellular senescence and ageing research demonstrates that interventions enhancing mitochondrial clearance can slow age-related functional decline across multiple tissues, suggesting that mitochondrial maintenance represents a fundamental mechanism of ageing rather than a consequence of it.
The mitochondrial dysfunction cascade across the lifespan
Progressive accumulation of dysfunctional mitochondria drives age-related multi-system decline through oxidative stress and chronic inflammation
Source: Signal Transduction and Targeted Therapy (2025) | Georgian Medical Journal News
Unifying pathology: why diverse diseases share common mechanisms
Neurodegenerative diseases, cardiovascular disease, diabetes, obesity, autoimmune disorders, sepsis, and cancer represent clinically distinct entities with different genetic risk factors, environmental triggers, and organ-specific manifestations. Yet emerging evidence indicates they converge on mitochondrial dysfunction as a central pathological mechanism. This unified view reframes disease taxonomy: rather than treating seven unrelated conditions, clinicians might target the underlying mitochondrial failure that manifests differently across tissues.
In neurodegenerative disease, mitochondrial energy failure in neurons leads to accumulation of misfolded proteins and neuronal death. In diabetes, mitochondrial dysfunction in pancreatic beta cells impairs insulin secretion, while in muscle and liver, it promotes insulin resistance. In cardiovascular disease, cardiomyocyte energy failure drives pump dysfunction. In cancer, mitochondrial reprogramming enables metabolic evasion of immune surveillance and accelerated proliferation. The tissue manifestation differs, but the underlying pathophysiology—failed mitochondrial function—remains constant. Evidence for this unified mechanism appears in cancer metabolism and immunology literature.
This convergence suggests that a mitochondrial-focused approach to prevention and treatment might simultaneously improve outcomes across multiple seemingly independent disease categories. Rather than developing separate therapies for each condition, interventions that restore mitochondrial function could provide broad therapeutic benefit.
What this means
Limitations of antioxidant-only approaches
Current antioxidant-based therapies address oxidative damage after it occurs, attempting to neutralize reactive oxygen species chemically. However, this approach treats the symptom rather than the mechanism. According to mitochondrial biology research, the critical question is not merely the presence of oxidative damage, but rather: where does the damage occur, why does it accumulate at that location, and can the cell remove the damaged machinery?
A mitochondrion with impaired energy production will generate oxidative stress regardless of antioxidant supplementation. Conversely, a cell with robust mitochondrial function can handle substantial oxidative challenges through endogenous antioxidant enzyme systems. The problem is not the existence of reactive oxygen species—they serve essential signalling functions—but rather the cell’s inability to manage them through proper mitochondrial turnover and quality control. Evidence from clinical trials of antioxidant supplementation shows limited benefit in slowing ageing or preventing age-related disease, supporting this mechanistic view.
Frequently asked questions
If mitochondrial dysfunction causes so many diseases, why hasn’t this framework been adopted clinically?
Historically, diseases have been studied within organ-based silos—cardiology, neurology, endocrinology—each developing disease-specific treatments. Mitochondrial dysfunction as a unifying principle requires integrative thinking across specialties and regulatory frameworks organised by organ systems. Additionally, mitochondrial dysfunction is a mechanistic driver, not a simple biomarker; establishing its presence requires functional assessment (respiratory capacity, bioenergetic capacity) rather than routine clinical chemistry. Broader adoption requires new diagnostic tools and organisational change in medical practice.
What interventions currently available support mitochondrial health?
Aerobic exercise increases mitochondrial biogenesis and improves quality control mechanisms; caloric restriction and intermittent fasting enhance mitophagy; sleep deprivation impairs mitochondrial function while adequate sleep supports it. Compounds including NAD+ precursors, coenzyme Q10, and polyphenols show promise in animal models, though human clinical trial data remain limited. The most evidence-supported interventions are lifestyle-based: sustained aerobic activity, metabolic stability, and adequate sleep.
Can mitochondrial dysfunction be measured clinically today?
Direct measurement requires specialized testing (high-resolution respirometry, magnetic resonance spectroscopy) available primarily in research centres. Indirect biomarkers including lactate metabolism, circulating oxidative stress markers, and exercise tolerance testing provide approximate assessment in clinical settings. As the mitochondrial dysfunction framework gains acceptance, standardized clinical biomarkers suitable for routine practice are expected to emerge.
The emerging view of mitochondria as cellular decision-makers rather than mere power plants represents a fundamental reorientation of how researchers and clinicians understand health, ageing, and disease. This framework unifies previously disparate pathologies, explains why prevention strategies appear effective across multiple disease categories, and identifies specific cellular mechanisms amenable to intervention. As diagnostic tools and therapeutic approaches grounded in mitochondrial biology mature, clinical practice may shift toward earlier assessment of mitochondrial function and broader prevention strategies targeting the cellular energy systems that sustain health across the lifespan.
Source: Signal Transduction and Targeted Therapy (2025), DOI: 10.1038/s41392-025-02253-4
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
